Increased serum nesfatin-1 levels in patients with inflammatory bowel diseases
Autor: | Erdem Akbal, Sengul Beyaz |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
medicine.medical_specialty Adipokine Adipose tissue Inflammation Gastroenterology Inflammatory bowel disease Proinflammatory cytokine 03 medical and health sciences 0302 clinical medicine Adipokines Crohn Disease Internal medicine medicine Humans Nucleobindins 030304 developmental biology 0303 health sciences biology business.industry C-reactive protein General Medicine medicine.disease Inflammatory Bowel Diseases Ulcerative colitis C-Reactive Protein biology.protein 030211 gastroenterology & hepatology Colitis Ulcerative medicine.symptom business Body mass index Biomarkers |
Zdroj: | Postgraduate medical journal. 98(1160) |
ISSN: | 1469-0756 |
Popis: | Background Adipokines are adipose tissue–derived secreted molecules that can exert anti-inflammatory or proinflammatory activities. Altered expression of adipokines has been described in various inflammatory diseases, including inflammatory bowel diseases (IBDs) such as Crohn's disease (CD) and ulcerative colitis (UC). Little is known about nesfatin-1, a recently identified adipokine, in IBD. The aim of this study was to investigate serum nesfatin-1 levels in patients with IBD. Methods This study included a total of 52 adult individuals (17 patients with CD, 18 patients with UC and 17 healthy volunteers) with similar age and body mass index. Serum nesfatin-1 levels were measured by ELISA in healthy individuals and patients with IBD in their active and remission periods. Blood inflammation markers including C reactive protein (CRP), erythrocyte sedimentation (ESR) and white cell count (WCC) were also measured in patients. Results We found significantly elevated levels of serum nesfatin-1 in the active disease period in both patients with CD (p=0.00003) and patients with UC (p=0.00001), compared with healthy individuals. Serum nesfatin-1 levels moderately decreased in the remission period; however, they were still significantly higher than that of healthy individuals. Receiver operating characteristic curve analyses indicated serum nesfatin-1 with an excellent diagnostic value for IBD. Finally, patients had significantly high CRP, ESR and WCC in the active IBD; however, we found the nesfatin-1 strongly correlated only with ESR in the active CD. Conclusion This is the first study investigating the circulating levels of nesfatin-1 in patients with IBD. Serum nesfatin-1 may serve as an additional inflammatory marker for diagnosis of IBD in affected individuals. |
Databáze: | OpenAIRE |
Externí odkaz: |